{
    "patient": {
        "Name": "Marilyn Mcbride",
        "DateOfBirth": "2000-04-16",
        "Sex": "Male",
        "Diagnosis": "Large cell carcinoma",
        "BodyPart": "Lung",
        "Physician": "Dr. Jennifer Johnson",
        "TreatingInstitution": "Gutierrez Group"
    },
    "specimen": {
        "Tumor specimen": {
            "source": "Lung",
            "CollectedDate": "2023-12-29",
            "ReceivedDate": "2023-12-29",
            "TumorPercentage": "72%"
        },
        "Normal specimen": {
            "source": "Blood",
            "CollectedDate": "2024-01-02",
            "ReceivedDate": "2024-01-07"
        }
    },
    "genomic variants": {
        "Somatic - Potentially Actionable": [
            {
                "Gene": "NF1",
                "DNA Alteration": "c.4394A>G",
                "GeneMutation": "p.S2309Cfs*10 Frameshift-LOF",
                "VariantAlleleFraction": "3.51%"
            }
        ],
        "Somatic - Biologically Relevant": [
            {
                "Gene": "IKZF1",
                "DNA Alteration": "c.3113A>G",
                "GeneMutation": "p.N1465S Missensevariant(exon2)-GOF",
                "VariantAlleleFraction": "18.76%"
            },
            {
                "Gene": "MPL",
                "DNA Alteration": "c.1543_1545delinsAAA",
                "GeneMutation": "p.W515K Spliceregionvariant-GOF",
                "VariantAlleleFraction": "21.92%"
            }
        ],
        "Germline - Pathogenic": [],
        "Pertinent Negatives": [
            "CSF1R",
            "HBB",
            "ERCC2",
            "IDH1"
        ]
    },
    "immunotherapy markers": [
        {
            "marker_name": "Tumor Mutational Burden",
            "TmbValue": "18 m/Mb",
            "Tmbpercentile": "89%",
            "Status type": "Microsatellite Instability Status",
            "statusvalue": "Stable"
        }
    ],
    "FDA-Approved Therapies": {
        "Current Diagnosis": [
            {
                "Mechanism": "KRAS G12C Inhibitors",
                "Medication": "Sotorasib",
                "Recommendations": [
                    "NCCN, Consensus, Non-Small Cell Lung Cancer",
                    "MSK OncoKB, Level 1"
                ],
                "Relevant Mutation": "KRASp.G12C G12C-GOF"
            }
        ],
        "Other Indications": [
            {
                "Mechanism": "KRAS G12C Inhibitors",
                "Medication": "Sotorasib",
                "Recommendations": [
                    "NCCN, Consensus, Non-Small Cell Lung Cancer",
                    "MSK OncoKB, Level 1"
                ],
                "Relevant Mutation": "KRASp.G12C G12C-GOF"
            }
        ]
    },
    "Additional Indicators": [
        {
            "description": "Unfavorable Prognosis",
            "therapy": "NCCN, Consensus, Non-Small Cell Lung Cancer",
            "mutation": "KRASp.G12C Gain-of-function"
        }
    ],
    "Clinical trials": [
        {
            "description": "A Study of VS-6766 v. VS-6766 + Defactinib in Recurrent G12V, Other KRAS and BRAF Non-Small Cell Lung Cancer ",
            "phase": "Phase 2",
            "mutations": [
                "KRAS"
            ]
        },
        {
            "description": "A Phase 1/2 Study of MRTX849 in Patients With Cancer Having a KRAS G12C Mutation KRYSTAL-1",
            "phase": "Phase 1/2",
            "mutations": [
                "KRAS",
                "STK11"
            ]
        },
        {
            "description": "First-in-human Study of DRP-104 (Sirpiglenastat) as Single Agent and in Combination With Atezolizumab in Patients With Advanced Solid Tumors. (NCT04471415)",
            "phase": "Phase 1/2",
            "mutations": [
                "NFE2L2",
                "STK11"
            ]
        }
    ],
    "variants of unknown significance": {
        "Somatic": [
            {
                "Gene": "DICER1",
                "DNA Alteration": "c.5492G>A",
                "GeneMutation": "p.E1705V Frameshift-GOF",
                "VariantAlleleFraction": "10.63%"
            },
            {
                "Gene": "HBB",
                "DNA Alteration": "c.364G>A",
                "GeneMutation": "p.E27K Spliceregionvariant-GOF",
                "VariantAlleleFraction": "18.81%"
            },
            {
                "Gene": "MYO1G",
                "DNA Alteration": "c.145G>A",
                "GeneMutation": "p.V49M Nonsense-GOF",
                "VariantAlleleFraction": "3.43%"
            },
            {
                "Gene": "TLR8",
                "DNA Alteration": "c.3113A>G",
                "GeneMutation": "p.N515H Missensevariant(exon2)-GOF",
                "VariantAlleleFraction": "2.28%"
            },
            {
                "Gene": "PHF6",
                "DNA Alteration": "c.3113A>G",
                "GeneMutation": "p.R225X Spliceregionvariant-GOF",
                "VariantAlleleFraction": "3.88%"
            },
            {
                "Gene": "BRCA2",
                "DNA Alteration": "c.5946delT",
                "GeneMutation": "p.S1982Rfs*22 Nonsense-GOF",
                "VariantAlleleFraction": "8.32%"
            },
            {
                "Gene": "PHF6",
                "DNA Alteration": "c.3113A>G",
                "GeneMutation": "p.R225X Spliceregionvariant-GOF",
                "VariantAlleleFraction": "3.86%"
            }
        ],
        "Germline": [
            {
                "Gene": "SDHB",
                "DNA Alteration": "c.487T>C",
                "GeneMutation": "p.S163P Nonsense-LOF",
                "Condition": "recent"
            }
        ]
    },
    "low coverage regions": [
        "MAPK1",
        "PIK3CA"
    ],
    "genomic variants details": {
        "Somatic Variant Details - Potentially Actionable": [
            {
                "Gene": "NF1",
                "DNA Alteration": "c.4394A>G",
                "GeneMutation": "p.S2309Cfs*10 Frameshift-LOF",
                "description": "FAT1 encodes a transmembrane protein involved in tumor suppressor signaling. FAT1 protein can regulate transcriptional activity by sequestering beta-catenin, thereby preventing it from entering the nucleus. Loss of function mutations and copy number loss of FAT1 are associated with cancer progression.",
                "VariantAlleleFraction": "3.51%"
            }
        ],
        "Somatic Variant Details - Biologically Relevant": [
            {
                "Gene": "IKZF1",
                "DNA Alteration": "c.3113A>G",
                "GeneMutation": "p.N1465S Missensevariant(exon2)-GOF",
                "description": "FAT1 encodes a transmembrane protein involved in tumor suppressor signaling. FAT1 protein can regulate transcriptional activity by sequestering beta-catenin, thereby preventing it from entering the nucleus. Loss of function mutations and copy number loss of FAT1 are associated with cancer progression.",
                "VariantAlleleFraction": "18.76%"
            },
            {
                "Gene": "MPL",
                "DNA Alteration": "c.1543_1545delinsAAA",
                "GeneMutation": "p.W515K Spliceregionvariant-GOF",
                "description": "KRAS is a GDP/GTP binding protein that acts as an intracellular signal transducer. KRAS is involved in several pathways involved in cellular proliferation and survival, including the PI3K-AKT-mTOR pathway and the Ras-Raf-MEK-ERK pathway. Activating mutations, copy number gains, and overexpression of KRAS are associated with cancer progression.",
                "VariantAlleleFraction": "21.92%"
            }
        ]
    },
    "clinical history": {
        "Date": "2023-12-27"
    },
    "other": {
        "ReportId": "5191",
        "ReportDate": "2024-01-05",
        "SignedBy": "Jennifer Johnson",
        "Supervisor": "Dr. Tammy Farley"
    }
}